ReviewBritish journal of cancer2016
Targeting cell death signalling in cancer: minimising 'Collateral damage'.
Review in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 66 citations in OpenAlex.
- Lupeol- and Cis-Vaccenic Acid-Containing Bioactive Fraction ofBiomolecules · 2026Article
- Morphoregulatory ADD3 underlies glioblastoma growth and formation of tumor-tumor connections.Life science alliance · 2025Article
- Comprehensive landscape of cell death mechanisms: from molecular cross-talk to therapeutic innovation in oncology.Frontiers in cell and developmental biology · 2025Review
- Development of Novel Class of Phenylpyrazolo[3,4-International journal of molecular sciences · 2023Article
- Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers.Cell death and differentiation · 2022Article
- A combinatorial approach to protect sensory tissue against cisplatin-induced ototoxicity.Hearing research · 2022Article
- Design and synthesis of novel (Z)-5-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)-3-((1-substituted phenyl-1H-1,2,3-triazol-4-yl)methyl)thiazolidine-2,4-diones: a potential cytotoxic scaffolds and their molecular modeling studies.Molecular diversity · 2021Article
- Molecular mechanisms and associated cell signalling pathways underlying the anticancer properties of phytochemical compounds fromExperimental and therapeutic medicine · 2021Review
- Treating MCF7 breast cancer cell with proteasome inhibitor Bortezomib restores apoptotic factors and sensitizes cell to Docetaxel.Medical oncology (Northwood, London, England) · 2021Article
- Contribution of cell death signaling to blood vessel formation.Cellular and molecular life sciences : CMLS · 2021Review
- Article
- Potential Roles of Acute Phase Proteins in Cancer: Why Do Cancer Cells Produce or Take Up Exogenous Acute Phase Protein Alpha1-Antitrypsin?Frontiers in oncology · 2021Review
- Article
- Dehydrocostus lactone inhibits cell proliferation and induces apoptosis by PI3K/Akt/Bad and ERS signalling pathway in human laryngeal carcinoma.Journal of cellular and molecular medicine · 2020Article
- The Synergistic Antitumor Effect of 5-Fluorouracil Combined with Allicin against Lung and Colorectal Carcinoma Cells.Molecules (Basel, Switzerland) · 2020Article
- Germacrone Inhibits Cell Proliferation and Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cells.BioMed research international · 2020Article
- One-Pot Radiosynthesis and Biological Evaluation of a Caspase-3 Selective 5-[Scientific reports · 2019Article
- In vitro investigating of anticancer activity of new 7-MEOTA-tacrine heterodimers.Journal of enzyme inhibition and medicinal chemistry · 2019Article
- Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models.Science advances · 2019Article
- Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Targeting apoptosis for the treatment of cancer has become an increasingly attractive strategy, with agents in development to trigger extrinsic apoptosis via TRAIL signalling, or to prevent the anti-apoptotic activity of BCL-2 proteins or inhibitor of apoptosis (IAP) proteins. Although the evasion of apoptosis is one of the hallmarks of cancer, many cancers have intact apoptotic signalling pathways, which if unblocked could efficiently kill cancerous cells. However, it is becoming increasing clear that without a detailed understanding of both apoptotic and non-apoptotic signalling, and the key proteins that regulate these pathways, there can be dose-limiting toxicity and adverse effects associated with their modulation. Here we review the main apoptotic pathways directly targeted for anti-cancer therapy and the unforeseen consequences of their modulation. Furthermore, we highlight the importance of an in-depth mechanistic understanding of both the apoptotic and non-apoptotic functions of those proteins under investigation as anti-cancer drug targets and outline some novel approaches to sensitise cancer cells to apoptosis, thereby improving the efficacy of existing therapies when used in combination with novel targeted agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.